Derivation Web

claim_ca1c029be8df451a

**Selected angle:** `source`

## One-sentence thesis

The direct receipts support a narrow working claim: Objective response was observed in 9 (21%) patients, including 2 complete responses (CR), 3 CRi, and 4 morphologic leukemia‐free state (MLFS); Responses were observed in 4 (50%) of 8 RUNX1‐mutated patients. The context receipts provide source breadth and boundary checks, not independent confir…

source_40c191fa6bb44663

**Selected angle:** `source`

## One-sentence thesis

The direct receipts support a narrow working claim: Objective response was observed in 9 (21%) patients, including 2 complete responses (CR), 3 CRi, and 4 morphologic leukemia‐free state (MLFS); Responses were observed in 4 (50%) of 8 RUNX1‐mutated patients. The context receipts provide source breadth and boundary checks, not independent confir…

source_f04c93eed8e84b35

{"publication_id": "1a265041-dcba-4d47-9a2a-af0e73104267", "traces": [{"candidate_sources": [{"doi": "10.1002/ajh.25000", "study": "Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies", "url": null}, {"doi": "10.1200/jco.23.01075", "study": "Long-Term Results of the Dasatinib-Bl…

source_55d1b69d709445be

{"content_hash": null, "edges": [{"from": "1a265041-dcba-4d47-9a2a-af0e73104267", "to": "claim_1", "type": "contains_claim"}, {"from": "1a265041-dcba-4d47-9a2a-af0e73104267", "to": "claim_2", "type": "contains_claim"}, {"from": "1a265041-dcba-4d47-9a2a-af0e73104267", "to": "claim_3", "type": "contains_claim"}, {"from": "1a265041-dcba-4d47-9a2a-af0e73104267", "to": "claim_4", "type": "contains_clai…

source_4cb8c5b083fd491a

{"contradictions": ["Real tension: the useful signal is narrower than the topic label. The lead receipts support the core claim, while the added A/B context receipts define where that claim may generalize, fail, or need a separate extraction.", "_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._"], "limitations": ["This is an agent-assist…

source_927d2c6b22334fde

study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness
Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Long-Term Results of t…

source_0f2910f85ca84b54

{"method_note": "Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.", "publication_id": "1a265041-dcba-4d47-9a2a-af0e73104267", "sources": [{"directness": "primary", "doi": "10.1002/ajh.25000", "risk_of_bias": "not appraised in public sidecar", "study": "Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in co…

source_474bf80e012b4767

{"decision": "accept", "gate_failures": [], "notes": ["accepted and queued for publish"], "review_recommendation": "accept"}